Midline and central lesions of the brain requiring conventional radiation therapy (RT) present complex difficulties in dose avoidance to organs at risk (OAR). In either the definitive or adjuvant setting, proper RT coverage of these lesions involves unnecessary treatment of large volumes of normal brain. We propose a class solution for these lesions using proton therapy (PrT).
Neil C. Estabrook, MD, Kevin P. McMullen, MD, Mark W. McDonald, MD, Hoene A. Ted, MS, CMD, Peter A. Johnstone, MD, FACR, Jeffrey C. Buchsbaum, MD, PhD, AM; IU Health Proton Therapy Center, Indiana University School of Medicine
Objective: Midline and central lesions of the brain requiring conventional radiation therapy (RT) present complex difficulties in dose avoidance to organs at risk (OAR). In either the definitive or adjuvant setting, proper RT coverage of these lesions involves unnecessary treatment of large volumes of normal brain. We propose a class solution for these lesions using proton therapy (PrT).
Materials and Methods: The records of the IU Health Proton Therapy Center were reviewed for patients presenting between January 1, 2009 and March 1, 2013 with midline central nervous system (CNS) lesions. Nine patients were identified. After institutional review board (IRB) approval was granted, their dosimetry was reviewed for target volume doses and OAR dose avoidance.
Results: Most of these cases were craniopharyngiomas (five cases); the others were meningiomas (four cases). In all nine cases, fields that were formed by the vertex and anterior and/or posterior superior oblique PrT beams along the midsagittal plane were used to provide coverage with minimal dose to the brainstem deep or to the cerebral hemispheres. The median prescribed dose using only midsagittal fields to target planning target volume (PTV) was 52.2 Gy relative biological effectiveness (RBE) (range: 48.6–61.2 Gy RBE), with a mean dose of 53.2 Gy RBE. The average of the mean doses to the brainstems using these fields in the nine plans was 18.0 Gy RBE (range: 0.0–40.1 Gy RBE). Similarly, the average of the mean doses to the hippocampi was 17.1 Gy RBE (range: 0.0–45.9 Gy RBE).
Conclusions: We consider these patients to be optimally treated with PrT and preferentially refer patients whenever possible. The use of modified midsagittal PrT schemas allows for treatment of midline CNS lesions with sparing of most of the uninvolved brain.
Frontline Chemo-Free Regimen Supported in HR+/HER2+ Breast Cancer Therapy
January 1st 2024Combining anastrozole with palbociclib, trastuzumab, and pertuzumab as a frontline therapy for hormone receptor–positive, HER2-positive breast cancer may avoid some of the toxicities associated with chemotherapy, says Amy Tiersten, MD.
Oncology On-The-Go Podcast: ASCO 2023 Recap
June 19th 2023Experts from University of California, Los Angeles Health and Mayo Clinic discuss key data presented at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting in the gynecologic and gastrointestinal cancer spaces and how they may impact patient care.